Efficacy of Platelet-rich Plasma in Management of Anosmia
NCT06930248 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2025-04-16
Summary
Olfactory dysfunction is a prevalent disorder that affects up to 20% of the general population and has significant effects on a person's quality of life as well as increased morbidity and mortality (Croy I et al., 2014;Nordin S et al
.,2008). Anosmia is the inability to perceive the odor or a lack of functioning olfaction; it may be temporary or permanent. Organic anosmia is loss of smell due to nasal obstruction caused by sinonasal diseases (as nasal polyps, tumors, postoperative) preventing odorant molecules from reaching olfactory mucosa. Functional anosmia affects up to 5% of the general population and 10% of those older than 65 . Functional anosmia is due to damage of peripheral olfactory area causing permanent loss of smell as post-traumatic, post viral infection. . 20% of individuals aged 20 to 90 years have impaired olfactory Function . The etiology of olfactory dysfunction is quite varied, including post viral posttraumatic, and idiopathic loss of smell. Unfortunately, with these etiologies, the likelihood of spontaneous recovery is generally poor with only approximately one-third of people regaining function and the duration of loss negatively correlating with recovery rate . Treatment for olfactory dysfunction is also limited. Best evidence studies recommend olfactory training and topical steroid nasal irrigations as potential therapeutics, yet both have limited efficacy . PRP is an autologous materials known to have anti-inflammatory and proregenerative properties including up regulation of growth factors including transforming growth factor, vascular endothelial growth factor, epidermal growth factor, and insulin-like growth factor. It has been used as a safe therapy effective in treating inflammation, wound healing, and peripheral neuropathies in other clinical settings. In particular, PRP has been shown to promote axon regeneration and neuroregeneration .
Conditions
- Anosmia
Interventions
- BIOLOGICAL
-
Platelet rich plasma injection
Our first step is the local anesthesia using a solution of decongestion nasal drops with 5% Emla and 10% Xylocaine spray in cotton, which is placed in the nose for 30 minutes. The 2nd step of the administration is the PRP injection in the olfactory area of the noseVia1 ml syringe with 30 G needle, PRP is injected in the olfactory area(located at superior turbinate and superior portion of lateral an medial portion of nasal cavity) approximately every 1 cm2 with the help of a nasal endoscope. The procedure is repeated 3 times with a 4 week interval with follow up patients for 6 months. A 4th time is injected after 3 months.
Sponsors & Collaborators
-
Sohag University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-05-01
- Primary Completion
- 2026-05-01
- Completion
- 2026-05-01
More Related Trials
-
"Platelet Rich Plasma for the Management of Post-Viral Olfactory Dysfunction.
NCT05666492 ·Status: UNKNOWN ·Phase: NA
-
Nasal Obstruction and Olfactory Losses
NCT05920330 ·Status: RECRUITING ·Phase: NA
-
Stellate Ganglion Block with Lidocaine for the Treatment of COVID-19-Induced Parosmia
NCT06055270 ·Status: RECRUITING ·Phase: PHASE3
-
Stellate Ganglion Block for COVID-induced Parosmia
NCT06253806 ·Status: COMPLETED ·Phase: PHASE2
-
Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction
NCT05445921 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
COVID-19 Anosmia Study
NCT04495816 ·Status: COMPLETED ·Phase: PHASE2
-
Coronavirus Smell Therapy for Anosmia Recovery
NCT04422275 ·Status: WITHDRAWN ·Phase: PHASE2
-
Preparation and Characterization Intranasal Film Loaded With Steroid as a Local Treatment of Anosmia in Compare to Insulin Intranasal Film
NCT05328414 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease
NCT04569825 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Trial of Directed High-dose Nasal Steroids on Residual Smell Loss in Sinus Patients After Sinus Surgery
NCT01814618 ·Status: WITHDRAWN ·Phase: PHASE2
-
Acupuncture Therapy for COVID-Related Olfactory Loss
NCT04952389 ·Status: COMPLETED ·Phase: NA
-
Study of the Pathogenesis of Olfactory Disorders in COVID-19
NCT04366934 ·Status: COMPLETED
-
Anosmia and Covid-19
NCT05246059 ·Status: COMPLETED ·Phase: NA
-
Laser Assisted Treatment of Chronic Sinusitis With and Without Light Activated Agents
NCT00948519 ·Status: UNKNOWN ·Phase: NA
-
A Clinical Study to Evaluate the Safety and Efficacy of Platelet Rich Plasma Injection for Atrophic Rhinitis
NCT03112330 ·Status: COMPLETED ·Phase: NA
-
NAC Trial for Anosmia
NCT02481609 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19)
NCT04374474 ·Status: WITHDRAWN ·Phase: PHASE4
-
Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.
NCT06892704 ·Status: RECRUITING
-
Characteristics of the Anosmic Olfactory Mucosa
NCT05562050 ·Status: ACTIVE_NOT_RECRUITING
-
Olfactory Training in Chronic Rhinosinusitis
NCT03055572 ·Status: WITHDRAWN ·Phase: NA
-
The Optimal Head Position for Distributing Topical Nasal Medication Using the Mucosal Atomization Device
NCT02079792 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)
NCT05855369 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Coblation in Endoscopic Sinus Surgery
NCT01793987 ·Status: UNKNOWN ·Phase: NA
-
Simvastatin Nasal Rinses for the Treatment of COVID-19 Mediated Dysomsia
NCT05542095 ·Status: WITHDRAWN ·Phase: PHASE1
-
Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity
NCT04361474 ·Status: COMPLETED ·Phase: PHASE3